Latest Executive Remuneration News

Microequities Asset Management Group saw a 20.1% drop in profit after tax for FY26, hit by sharp valuation falls in tech-heavy portfolios amid AI fears, despite a 1.5% revenue rise and a strong balance sheet.

MFF Capital reported a sharp 63% fall in net profit for FY26 but declared a higher fully franked dividend, underpinned by a disciplined long-term investment approach and leadership changes.

Orora’s FY26 results reveal a $616.6 million statutory loss driven by a $742.8 million Glass impairment, offset by robust growth in its Cans business and disciplined capital management.

Telstra Group Limited posted modest revenue decline but growth in profit and earnings per share for FY26, alongside a 10.5% dividend increase and a new $1 billion share buy-back. The company advances its Connected Future 30 strategy while managing a major July network outage.

Vital Healthcare Property Trust (NZX:VHP) delivered a robust FY26, marked by a successful management internalisation, 23.5% AFFO growth, and a stable distribution payout, underpinning its position as a leading healthcare infrastructure owner in Australasia.

SEEK Limited delivered solid operational growth with record dividends in FY2026, yet posted a hefty net loss driven by a $284m impairment on its Chinese associate Zhaopin and a $201m loss from its Growth Fund.

AGL Energy reported a 575% surge in statutory profit to $756 million for FY26, driven by strategic divestments and improved asset flexibility, while declaring a fully franked 50 cents dividend and progressing its energy transition with 12 GW of renewable capacity targeted by 2035.

Chrysos Corporation posted a 33% revenue increase and 68% EBITDA growth in FY26, driven by expanding its PhotonAssay™ technology fleet to 46 units worldwide and signing 24 new lease agreements.

CAR Group Limited reported a 14% increase in net profit after tax to AUD 332.4 million for FY26, driven by strong revenue growth and AI innovation across its global vehicle marketplaces.

Percheron Therapeutics announces Dr Michael Baker as incoming CEO, replacing Dr James Garner who steps down after three years. Baker’s appointment aligns executive incentives with shareholder value as the company prepares for a pivotal HMBD-002 clinical trial.

Ava Risk Group has appointed Bryant Henson as CEO to spearhead its next growth phase, with a sharp focus on expanding its footprint in the United States and strengthening commercial execution worldwide.

Neometals Ltd implements a significant 25% cut in cash personnel costs by reducing director and staff salaries, while introducing retention performance rights to key executives to maintain strategic momentum.